Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

16.39CHF
11:08am GMT
Change (% chg)

CHF-0.08 (-0.49%)
Prev Close
CHF16.47
Open
CHF16.50
Day's High
CHF16.63
Day's Low
CHF16.25
Volume
27,943
Avg. Vol
337,011
52-wk High
CHF30.70
52-wk Low
CHF15.20

Latest Key Developments (Source: Significant Developments)

Santhera Calls EGM And Proposes Ordinary Share Capital Increase
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::SANTHERA CALLS EXTRAORDINARY GENERAL MEETING AND PROPOSES ORDINARY SHARE CAPITAL INCREASE TO RAISE APPROXIMATELY CHF 50 MILLION.CAPITAL INCREASE TO BE EFFECTED BY WAY OF AN ACCELERATED BOOK BUILDING.CAPITAL INCREASE TO FINANCE INITIAL PAYMENT OF USD 20 MILLION TO IDORSIA FOR RIGHTS TO VAMOROLONE.CAPITAL INCREASE ALSO TO FINANCE DEVELOPMENT OF VAMOROLONE AND TO FUND ITS ONGOING ACTIVITIES.WILL ISSUE 1,000,000 NEW REGISTERED SHARES TO IDORSIA FROM ITS EXISTING AUTHORIZED CAPITAL.  Full Article

Santhera Enters Into Agreement To Buy Option From Idorsia For Exclusive Sub-License Of First-In-Class Dissociative Steroid Vamorolon
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::SANTHERA ENTERS INTO AGREEMENT TO ACQUIRE OPTION FROM IDORSIA FOR EXCLUSIVE SUB-LICENSE OF FIRST-IN-CLASS DISSOCIATIVE STEROID VAMOROLON.IDORSIA TO BECOME LARGEST SHAREHOLDER IN SANTHERA WITH A 13.3% EQUITY STAKE.  Full Article

Idorsia Maintains Collaboration Agreement With Reveragen
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Idorsia Ltd ::MAINTAINS COLLABORATION AGREEMENT WITH REVERAGEN.FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT.  Full Article

Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - IDORSIA LTD ::SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN.SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS HAS FILED A COMPLAINT AGAINST ACTELION.BELIEVES THAT SUCH CLAIM HAS NO MERIT.  Full Article

Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - IDORSIA LTD ::US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION.NON-GAAP* OPERATING RESULTS 9M 2018: LOSS OF CHF 247 MILLION.UNCHANGED GUIDANCE FOR 2018: NON-GAAP OPERATING EXPENSES OF AROUND CHF 390 MILLION.9MTH US GAAP NET LOSS AMOUNTED TO CHF 278 MILLION.  Full Article

Idorsia Launches Offering Of New Shares And Convertible Bonds
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Idorsia Ltd ::IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE.LAUNCHES OFFERING OF UP TO 11,912,000 NEW SHARES THROUGH AN ACCELERATED BOOKBUILDING PROCESS.OFFERING OF CHF 200 MILLION CONVERTIBLE BONDS.NET PROCEEDS WILL ALLOW TO FUND PHASE 3 DEVELOPMENT OF IDORSIA'S LATE-STAGE PIPELINE.BONDS WILL HAVE A MATURITY OF 6 YEARS.BONDS WILL BE OFFERED WITH A COUPON BETWEEN 0.50% AND 1.00%.BONDS WILL BE OFFERED WITH CONVERSION PREMIUM BETWEEN 30% AND 35% ABOVE BOOKBUILDING PRICE OF OFFER SHARES.  Full Article

Idorsia Initiates Precision - Phase 3 Study With Aprocitentan
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Idorsia Ltd ::IDORSIA INITIATES PRECISION - PHASE 3 STUDY WITH APROCITENTAN FOR RESISTANT HYPERTENSION MANAGEMENT.  Full Article

Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease
Wednesday, 16 May 2018 

May 16 (Reuters) - IDORSIA LTD ::IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE.  Full Article

Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018
Thursday, 19 Apr 2018 

April 19 (Reuters) - Idorsia Ltd ::IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018.US GAAP OPERATING RESULTS IN Q1 2018: LOSS OF CHF 74 MILLION.NON-GAAP* OPERATING RESULTS Q1 2018: LOSS OF CHF 67 MILLION.OUTLOOK 2018: NON-GAAP OPERATING EXPENSES OF AROUND CHF 390 MILLION.  Full Article

Idorsia Forms Research Collaboration With Roche In Field Of Cancer Immunotherapy
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - IDORSIA LTD ::IDORSIA FORMS RESEARCH COLLABORATION WITH ROCHE IN THE FIELD OF CANCER IMMUNOTHERAPY.PARTIES WILL COLLABORATE ON DISCOVERY OF PRODUCTS THROUGH FORMATION OF A JOINT COMMITTEE, CHAIRED BY IDORSIA.ROCHE WILL PAY IDORSIA AN UPFRONT PAYMENT OF CHF 15 MILLION.ROCHE CAN THEN EXCLUSIVELY LICENSE IDORSIA COMPOUNDS AND COMPOUNDS RESULTING FROM COLLABORATION, FOR FURTHER PAYMENT OF 35 MILLION.IDORSIA WILL BE ELIGIBLE TO RECEIVE ONE-TIME DEVELOPMENT AND REGULATORY MILESTONES OF UP TO CHF 410 MILLION.IDORSIA ALSO BE ENTITLED TO ONE-TIME MILESTONES BASED ON SALES THRESHOLDS, AND TIERED ROYALTIES ON ANNUAL NET SALES.  Full Article

Swiss stocks - Factors to watch on Jan. 7

ZURICH/BERLIN, Jan 7 The Swiss blue-chip SMI was seen opening 0.4 percent higher at 8,645 points, according to premarket indications from bank Julius Baer.